MAPK blockade, toxicities, pathogenesis and management

Moreira A, Lebbe C, Heinzerling L (2021)

Publication Type: Journal article, Review article

Publication year: 2021

Journal

Current Opinion in Oncology Lippincott, Williams & Wilkins

Book Volume: 33

Pages Range: 139-145

Journal Issue: 2

DOI: 10.1097/CCO.0000000000000710

Abstract

Purpose of review BRAF/MEK inhibitor has changed the treatment landscape in patients with advanced and metastatic melanoma with prolonged overall survival and progression-free survival. Since three treatment combinations exist with similar efficacy therapy decisions are often made based on the side effect profile. Additionally, on-target side effects or class effects have to be properly managed to ensure treatment adherence. Recent findings Sequential treatment with BRAF/MEK inhibition and immunotherapy might increase toxicity with a sepsis-like syndrome and triple therapy with concomitant BRAF/MEK inhibition and anti-PD1/PD-L1 antibody therapy induces severe side effects in the vast majority of patients. Toxicity of combination therapy with BRAF/MEK inhibitors is generally manageable, reversible and infrequently associated with treatment discontinuation. In case of persisting off-target effects the change to another combination therapy can resolve side effects.

Authors with CRIS profile

Lucie Heinzerling Department of Dermatology

Involved external institutions

Icahn School of Medicine at Mount Sinai US United States (USA) (US) University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne FR France (FR)

How to cite

APA:

Moreira, A., Lebbe, C., & Heinzerling, L. (2021). MAPK blockade, toxicities, pathogenesis and management. Current Opinion in Oncology, 33(2), 139-145. https://doi.org/10.1097/CCO.0000000000000710

MLA:

Moreira, Alvaro, Celeste Lebbe, and Lucie Heinzerling. "MAPK blockade, toxicities, pathogenesis and management." Current Opinion in Oncology 33.2 (2021): 139-145.

BibTeX: Download